Development and validation of a postoperative risk model for esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy
Patients with locally advanced ESCC treated with nICT followed by MIE who have a high pN stage and pathological evidence of nerve invasion may benefit from intensified adjuvant therapy to improve long-term survival.
Authors
- Xihao Xie (ORCID: https://orcid.org/0000-0003-4031-7742)
- Bomeng Wu (ORCID: https://orcid.org/0009-0004-0425-4064)
- Weibi Che
- Fengyuan Peng
- Jiangbo Lin (ORCID: https://orcid.org/0000-0002-2405-5490)
- Jiawei Huang (ORCID: https://orcid.org/0000-0001-7670-2971)
- Hai Zhang (ORCID: https://orcid.org/0000-0001-5133-0286)
- Cui Li (ORCID: https://orcid.org/0000-0002-0708-8899)
- Caihou Feng
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
- Gaozhou People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-08-04
- DOI
- https://doi.org/10.3389/fmed.2025.1608313
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00